---
title: Research advances of metabolomics in early diagnosis of hepatocellular carcinoma
date: '2022-10-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/36207936/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Zkrxt7ktlCbHBXEV3v65xxSnkSWNsJ1A6Fq3gBniKhGfIUslK&fc=20210907212339&ff=20221011215919&v=2.17.8
source: metablomics[MeSH Terms]
description: Primary liver cancer is the second leading cause of death from malignant
  tumors in China, and hepatocellular carcinoma (HCC) is the main type. The disease
  stage at the time of HCC diagnosis largely determines the efficacy of subsequent
  treatment. Due to the HCC screening among high-risk population has not yet popularized,
  and the current diagnose method of early HCC is not satisfactory, the early HCC
  diagnosis rate is less than 30% in China. Metabolomics research emerging in recent
  years ...
---
Primary liver cancer is the second leading cause of death from malignant tumors in China, and hepatocellular carcinoma (HCC) is the main type. The disease stage at the time of HCC diagnosis largely determines the efficacy of subsequent treatment. Due to the HCC screening among high-risk population has not yet popularized, and the current diagnose method of early HCC is not satisfactory, the early HCC diagnosis rate is less than 30% in China. Metabolomics research emerging in recent years ...